Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
AML is highly heterogeneous in pathogenesis, and CEBPA double-mutated (CEBPAdm) AML is a common type of leukemia in China. Currently, no targeted therapies for CEBPAdm, and chemotherapy and transplantation are still the treatment options for CEBPA double-mutated AML. At present, the "3+7" treatment induction regimen of cytarabine combined with anthracyclines is still the first-line recommended regimen. In our retrospective study, the intermediate dose HAD regimen produced a 3-year RFS of 84.7% and a 3-year OS of 92.8% in CEBPAdm AML. Therefore, this project intends to confirm the efficacy of intermediate-dose HAD in the treatment of CEBPA double-mutated AML is superior to the conventional treatment regimen through the multi-center RCT study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Diagnoza białaczki AML potwierdzona podle wytycznych WHO-2022 z mutacją CEBPA
- •Wiek od 14 do 55 lat
- •Ogólny stan zdrowia pozwalający na intensywne leczenie (ECOG 0-2)
- •Prawidłowe wyniki badań wątroby, nerek i serca (wykonane do 7 dni przed leczeniem)
- •Prawidłowa funkcja serca potwierdzona badaniem echokardiograficznym
✗ Disqualifies
- •Wcześniejsze leczenie chemioterapią z powodu białaczki
- •Równoczesny nowotwór innego narządu wymagający leczenia
- •Ciąża lub karmienie piersią
- •Poważne choroby serca, zawał w ostatnich 6 miesiącach, zaburzenia rytmu serca lub niewydolność serca
- •Poważne infekcje (nieuleczona gruźlica, grzybica płuc)
Simplified criteria — AI translation
Trial details
- Minimum age
- 14 Years
- Maximum age
- 54 Years
- Last updated (source)
- August 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Blood Hospital
Tianjin, China
Trial contact
Hui Wei, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.